Structure-activity studies on nociceptin/orphanin FQ: From full agonist, to partial agonist, to pure antagonist

Farmaco

Volumn 54, Issue 11-12, 1999, Pages 810-825

  Salvadori, Severo ^a   Guerrini, Remo ^a   Calo', Girolamo ^a   Regoli, Domenico ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Nociceptin; Nociceptin analogs; OP4, Bioassay, mouse vas deferens; Orphanin FQ; Receptor binding

Indexed keywords

NOCICEPTIN; NOCICEPTIN RECEPTOR; OPIATE AGONIST; OPIATE ANTAGONIST;

ANALGESIA; ANIMAL TISSUE; ARTICLE; BIOASSAY; MOUSE; NONHUMAN; PAIN; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; HUMANS; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; OPIOID PEPTIDES; RATS; RECEPTORS, OPIOID; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033429262     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-827X(99)00108-1     Document Type: Article

References (117)

1. Hamon M. The new approach to opioid receptors. N. S. Arch. Pharmacol. 358:1998;SA 5.3.
2. Bunzow J.R., Saez C., Mortrud M., Bouvier C., Williams J.T., Low M., Grandy D.K. Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a mu, delta or kappa opioid receptor type. FEBS Lett. 347:1994;284-288.
3. Wick M.J., Minnerath S.R., Lin X., Elde R., Law P.Y., Loh H.H. Isolation of a novel cDNA encoding a putative membrane receptor with high homology to the cloned mu, delta, and kappa opioid receptors. Brain Res. Mol. Brain Res. 27:1994;37-44.
4. Wang J.B., Johnson P.S., Imai Y., Persico A.M., Ozenberger B.A., Eppler C.M., Uhl G.R. cDNA cloning of an orphan opiate receptor gene family member and its splice variant. FEBS Lett. 348:1994;75-79.
5. Pan Y.X., Cheng J., Xu J., Rossi G., Jacobson E., Ryan-Moro J., Brooks A.I., Dean G.E., Standifer K.M., Pasternak G.W. Cloning and functional characterization through antisense mapping of a kappa 3-related opioid receptor. Mol. Pharmacol. 47:1995;1180-1188.
6. Osinski M.A., Pampusch M.S., Murtaugh M.P., Brown D.R. Cloning, expression and functional role of a nociceptin/orphanin FQ receptor in the porcine gastrointestinal tract (in process citation). Eur. J. Pharmacol. 365:1999;281-289.
7. 1, a novel member of the opioid receptor family-cloning, functional expression and localization. FEBS Lett. 341:1994;33-38.
8. Lachowicz J.E., Shen Y., Monsma F.J., Sibley D.R. Molecular cloning of a novel G protein coupled receptor related to the opiate receptor family. J. Neurochem. 64:1995;34-40.
9. Chen Y., Fan Y., Liu J., Mestek A., Tian M., Kozak C.A., Yu L. Molecular cloning, tissue distribution and chromosomal localization of a novel member of the opioid receptor gene family. FEBS Lett. 347:1994;279-283.
10. Reinscheid R.K., Nothacker H.P., Bourson A., Ardati A., Henningsen R.A., Bunzow J.R., Grandy D.K., Langen H., Monsma F.J. Jr., Civelli O. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science. 270:1995;792-794.
11. 1 receptor. Nature. 377:1995;532-535.
12. 1) peptide-stimulated [S-35]GTP gamma S binding in rat brain. Neuroreport. 7:1996;729-733.
13. Sim L.J., Childers S.R. Anatomical distribution of mu, delta, and kappa opioid- and nociceptin/orphanin FQ-stimulated [35S]guanylyl-5′-O-(gamma-thio)-triphosphate binding in guinea pig brain. J. Comp. Neurol. 386:1997;562-572.
14. Peluso J., LaForge K.S., Matthes H.W., Kreek M.J., Kieffer B.L., Gaveriaux-Ruff C. Distribution of nociceptin/orphanin FQ receptor transcript in human central nervous system and immune cells. J. Neuroimmunol. 81:1998;184-192.
15. Halford W.P., Gebhardt B.M., Carr D.J. Functional role and sequence analysis of a lymphocyte orphan opioid receptor. J. Neuroimmunol. 59:1995;91-101.
16. Civelli O., Nothacker H.P., Reinscheid R. Reverse physiology: discovery of the novel neuropeptide, orphanin FQ/nociceptin. Crit. Rev. Neurobiol. 12:1998;163-176.
17. 1 receptor. Eur. J. Pharmacol. 340:1997;1-15.
18. Yamamoto T., Nozaki-Taguchi N., Sakashita Y., Kimura S. Nociceptin/orphanin FQ: role in nociceptive information processing. Prog. Neurobiol. 57:1999;527-535.
19. Sandin J., Georgieva J., Schott P.A., Ogren S.O., Terenius L. Nociceptin/orphanin FQ microinjected into hippocampus impairs spatial learnig in rats. Eur. J. Neurosci. 9:1997;194-197.
20. Manabe T., Noda Y., Mamiya T., Katagiri H., Houtani T., Nishi M., Noda T., Takahashi T., Sugimoto T., Nabeshima T., Takeshima H. Facilitation of long-term potentiation and memory in mice lacking nociceptin receptors. Nature. 394:1998;577-581.
21. Stratford T.R., Holahan M.R., Kelley A.E. Injections of nociceptin into nucleus accumbens shell or ventromedial hypothalamic nucleus increase food intake. Neuroreport. 8:1997;423-426.
22. 1, stimulates feeding in rats. Neuroreport. 8:1996;369-371.
23. Bryant W., Janik J., Baumann M., Callahan P. Orphanin FQ stimulates prolactin and growth hormone release in male and female rats. Brain Res. 807:1998;228-233.
24. Doi N., Dutia M.B., Russell J.A. Inhibition of rat oxytocin and vasopressin supraoptic nucleus neurons by nociceptin in vitro. Neuroscience. 84:1998;913-921.
25. Berzetei-Gurske I.P., Schwartz R.W., Toll L. Determination of activity for nociceptin in the mouse vas deferens. Eur. J. Pharmacol. 302:1996;R1-R2.
26. Patel H.J., Giembycz M.A., Spicuzza L., Barnes P.J., Belvisi M.G. Naloxone-insensitive inhibition of acetylcholine release from parasympathetic nerves innervating guinea-pig trachea by the novel opioid, nociceptin. Br. J. Pharmacol. 120:1997;735-736.
27. Calo' G., Rizzi A., Bodin M., Neugebauer W., Salvadori S., Guerrini R., Bianchi C., Regoli D. Pharmacological characterization of nociceptin receptor: an in vitro study. Can. J. Physiol. Pharmacol. 75:1997;713-718.
28. Fischer, W.G. Forssmann, B.J. Undem, Nociceptin-induced inhibition of tachykinergic neurotransmission in guinea pig bronchus, J. Pharmacol. Exp. Ther. 285 (1998) 902-907.
29. Giuliani S., Maggi C.A. Inhibition of tachykinin release from peripheral endings of sensory nerves by nociceptin, a novel opioid peptide. Br. J. Pharmacol. 118:1996;1567-1569.
30. Giuliani S., Maggi C.A. Prejunctional modulation by nociceptin of nerve-mediated inotropic responses in guinea-pig left atrium. Eur. J. Pharmacol. 332:1997;231-236.
31. Helyes Z., Nemeth J., Pinter E., Szolcsanyi J. Inhibition by nociceptin of neurogenic inflammation and the release of SP and CGRP from sensory nerve terminals. Br. J. Pharmacol. 121:1997;613-615.
32. Kapusta D.R., Sezen S.F., Chang J.K., Lippton H., Kenigs V.A. Diuretic and antinatriuretic responses produced by the endogenous opioid-like peptide, nociceptin (orphanin FQ). Life Sci. 60:1997;PL15-PL21.
33. Giuliani S., Tramontana M., Lecci A., Maggi C.A. Effect of nociceptin on heart rate and blood pressure in anaesthetized rats. Eur. J. Pharmacol. 333:1997;177-179.
34. Giuliani S., Lecci A., Tramontana M., Maggi C.A. The inhibitory effect of nociceptin on the micturition reflex in anaesthetized rats. Br. J. Pharmacol. 124:1998;1566-1572.
35. Mollereau C., Simons M.J., Soularue P., Liners F., Vassart G., Meunier J.C., Parmentier M. Structure, tissue distribution, and chromosomal localization of the prepronociceptin gene. Proc. Natl. Acad. Sci. USA. 93:1996;8666-8670.
36. Nothacker H.P., Reinscheid R.K., Mansour A., Henningsen R.A., Ardati A., Monsma F.J., Watson S.J., Civelli O. Primary structure and tissue distribution of the orphanin FQ precursor. Proc. Natl. Acad. Sci. USA. 93:1996;8677-8682.
37. Okuda-Ashitaka E., Minami T., Tachibana S., Yoshihara Y., Nishiuchi Y., Kimura T., Ito S. Nocistatin, a peptide that blocks nociceptin action in pain transmission. Nature. 392:1998;286-289.
38. Rossi G.C., Mathis J.P., Pasternak G.W. Analgesic activity of orphanin FQ2, murine prepro-orphanin FQ141-157 in mice. Neuroreport. 9:1998;1165-1168.
39. Portoghese P.S. Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists. Trends Pharmacol. Sci. 10:1989;230-235.
40. Schwyzer R. Estimated conformation, orientation, and accumulation of dynorphin A-(1-13)-tridecapeptide on the surface of neutral lipid membranes. Biochemistry. 25:1986;4281-4286.
41. Reinscheid R.K., Higelin J., Henningsen R.A., Monsma F.J. Jr., Civelli O. Structures that delineate orphanin FQ and dynorphin A pharmacological selectivities. J. Biol. Chem. 273:1998;1490-1495.
42. 1 and kappa-opioid receptors are involved in recognition of nociceptin and dynorphin A. FEBS Lett. 427:1998;296-300.
43. 1 receptor and its complex with nociceptin. Protein. Eng. 11:1998;1163-1179.
44. Dooley C.T., Houghten R.A. Orphanin FQ: receptor binding and analog structure-activity relationships in rat brain. Life Sci. 59:1996;PL23-PL29.
45. Butour J.L., Moisand C., Mazarguil H., Mollereau C., Meunier J.C. Recognition and activation of the opioid receptor-like ORL 1 receptor by nociceptin, nociceptin analogs and opioids. Eur. J. Pharmacol. 321:1997;97-103.
46. 2 in rat brain, rat vas deferens and CHO cells expressing recombinant human nociceptin recetors. Br. J. Pharmacol. 127:1999;123-130.
47. Reinscheid R.K., Ardati A., Monsma F.J. Jr., Civelli O. Structure-activity relationship studies on the novel neuropeptide orphanin FQ. J. Biol. Chem. 271:1996;14 163-14 168.
48. Mathis J.P., Ryan-Moro J., Chang A., Hom J.S., Scheinberg D.A., Pasternak G.W. Biochemical evidence for orphanin FQ/nociceptin receptor heterogeneity in mouse brain. Biochem. Biophys. Res. Commun. 230:1997;462-465.
49. Varani K., Calo' G., Rizzi A., Merighi S., Toth G., Guerrini R., Salvadori S., Borea P.A., Regoli D. Nociceptin receptor binding in mouse forebrain membranes: thermodynamic characteristics and structure-activity relationships. Br. J. Pharmacol. 125:1998;1485-1490.
50. Adapa I.D., Toll L. Relationship between binding affinity and functional activity of nociceptin/orphanin FQ. Neuropeptides. 31:1997;403-408.
51. Calo' G., Rizzi A., Bogoni G., Neugebauer V., Salvadori S., Guerrini R., Bianchi C., Regoli D. The mouse vas deferens: a pharmacological preparation sensitive to nociceptin. Eur. J. Pharmacol. 311:1996;R3-R5.
52. Rizzi A., Calo' G., Trevisani M., Tognetto M., Fabbri L., Mapp C., Guerrini R., Salvadori S., Regoli D., Geppetti P. Nociceptin receptor activation inhibits tachykinergic non adrenergic non cholinergic contraction of guinea pig isolated bronchus. Life Sci. 64:1999;PL157-PL163.
53. Hughes J., Kosterlitz H.W., Leslie F.M. Effect of morphine on adrenergic transmission in the mouse vas deferens. Assessment of agonist and antagonist potencies of narcotic analgesics. Br. J. Pharmacol. 53:1975;371-381.
54. Gyang E.A., Kosterliz H.W. Agonist and antagonist actions of morphine-like drugs on the guinea pig isolated ileum. Br. J. Pharmacol. 27:1966;514-527.
55. Regoli D., Gobeil F. Geppetti P., Muller-Esterl W., Regoli D. Peptidergic G Protein Coupled Receptors. 1999;64-77 IOS Press, Amsterdam.
56. Regoli D., Boudon A., Fauchere J.L. Receptors and antagonists for substance P and related peptides. Pharmacol. Rev. 46:1994;551-599.
57. Mogil J.S., Grisel J.E., Reinscheid R.K., Civelli O., Belknap J.K., Grandy D.K. Orphanin FQ is a functional anti-opioid peptide. Neuroscience. 75:1996;333-337.
58. Mogil J.S., Grisel J.E., Zhangs G., Belknap J.K., Grandy D.K. Functional antagonism of mu-, delta- and kappa-opioid antinociception by orphanin FQ. Neurosci. Lett. 214:1996;131-134.
59. Connor M., Vaughan C.W., Chieng B., Christie M.J. Nociceptin receptor coupling to a potassium conductance in rat locus coeruleus neurones in vitro. Br. J. Pharmacol. 119:1996;1614-1618.
60. 2+ in the SH-SY5Y human neuroblastoma cell line. Br. J. Pharmacol. 118:1996;205-207.
61. Montiel J.L., Cornille F., Roques B.P., Noble F. Nociceptin/orphanin FQ metabolism: role of aminopeptidase and endopeptidase 24.15. J. Neurochem. 68:1997;354-361.
62. Yu J., Chait B.T., Toll L., Kreek M.J. Nociceptin in vitro biotransformation in human blood. Peptides. 17:1996;873-876.
63. Noble F., Roques B.P. Association of aminopeptidase N and endopeptidase 24.15 inhibitors potentiate behavioral effects mediated by nociceptin/orphanin FQ in mice. FEBS Lett. 401:1997;227-229.
64. Sandin J., Georgieva J., Silberring J., Terenius L. In vivo metabolism of nociceptin/orphanin FQ in rat hippocampus. Neuroreport. 10:1999;71-76.
65. Vlaskovska M., Kasakov L., Suder P., Silberring J., Terenius L. Biotransformation of nociceptin/orphanin FQ by enzyme activity from morphine-naive and morphine-treated cell cultures (in process citation). Brain Res. 818:1999;212-220.
66. Bigoni R., Giuliani S., Calo' G., Rizzi A., Guerrini R., Salvadori S., Regoli D., Maggi C.A. Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies. Naunyn. Schmiedebergs. Arch. Pharmacol. 359:1999;160-167.
67. 2 and orphanin FQ/Nociceptin (OFQ/N) produce similar cardiovascular and renal responses in conscious rats. J. Pharmacol. Exp. Ther. 289:1999;173-180.
68. Calo' G., Rizzi A., Marzola G., Guerrini R., Salvadori S., Beani L., Regoli D., Bianchi C. Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay. Br. J. Pharmacol. 125:1998;373-378.
69. Madeddu P., Salis M.B., Milia A.F., Emanueli C., Guerrini R., Regoli D., Calo' G. Cardiovascular effects of nociceptin in unanesthetized mice. Hypertension. 33:1999;914-919.
70. Guerrini R., Calo' G., Rizzi A., Bianchi C., Lazarus L.H., Salvadori S., Temussi P.A., Regoli D. Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide. J. Med. Chem. 40:1997;1789-1793.
71. Albrecht E., Samovilova N.N., Oswald S., Baeger I., Berger H. Nociceptin (orphanin FQ): high-affinity and high-capacity binding site coupled to low-potency stimulation of guanylyl-5′-O-(gamma-thio)-triphosphate binding in rat brain membranes. J. Pharmacol. Exp. Ther. 286:1998;896-902.
72. 2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist. J. Med. Chem. 41:1998;3360-3366.
73. 1 for chemical modification on nociceptin, a naturally occurring nociceptive peptide. J. Biol. Chem. 271:1996;23 642-23 645.
74. 1. J. Pharmacol. Exp. Ther. 283:1997;735-741.
75. Schwyzer R. Theodoropulos D. Peptides 1986. 1987;7-23 W. de Gruyter, New York.
76. Chavkin, A. Goldstein, Specific receptor for the opioid peptide dynorphin: structure-activity relationships, Proc. Natl. Acad. Sci. USA 78 (1981) 6543-6547.
77. Hibert M.F., Trumpp-Kallmeyer S., Bruinvels A., Hoflack J. Three-dimensional models of neurotransmitter G-binding protein-coupled receptors. Mol. Pharmacol. 40:1991;8-15.
78. Strader C.D., Fong T.M., Tota M.R., Underwood D., Dixon R.A. Structure and function of G protein-coupled receptors. Annu. Rev. Biochem. 63:1994;101-132.
79. Schiller P.W. Development of receptor-specific opioid peptide analogs. Prog. Med. Chem. 28:1991;301-340.
80. Hruby V.J., Gehrig C.A. Recent developments in the design of receptor specific opioid peptides. Med. Res. Rev. 9:1989;343-401.
81. Morley J.S. Structure-activity relationships of enkephalin-like peptides. Annu. Rev. Pharmacol. Toxicol. 20:1980;81-110.
82. 10]dynorphin A-(1-11) are highly selective for kappa-opioid receptors, J. Med. Chem. 35 (1992) 4638-4639.
83. Shaw J.S., Miller L., Turnbull M.J., Gormley J.J., Morley J.S. Selective antagonists at the opiate delta-receptor. Life Sci. 31:1982;1259-1262.
84. Schiller P.W., Weltrowska G., Schmidt R., Berezowska I., Nguyen T.M., Lemieux C., Chung N.N., Carpenter K.A., Wilkes B.C. Subtleties of structure-agonist versus antagonist relationships of opioid peptides and peptidomimetics. J. Recept. Signal Transduct. Res. 19:1999;573-588.
85. Temussi P.A., Salvadori S., Amodeo P., Bianchi C., Guerrini R., Tomatis R., Lazarus L.H., Picone D., Tancredi T. Selective opioid dipeptides. Biochem. Biophys. Res. Commun. 198:1994;933-939.
86. Bryant S.D., Salvadori S., Cooper P.S., Lazarus L.H. New delta-opioid antagonists as pharmacological probes. Trends Pharmacol. Sci. 19:1998;42-46.
87. Guerrini R., Calo' G., Rizzi A., Bigoni R., Bianchi C., Salvadori S., Regoli D. A new selective antagonist of the nociceptin receptor. Br. J. Pharmacol. 123:1998;163-165.
88. 2, a novel selective nociceptin receptor antagonist (1999), The 30th International Narcotics Research Conference meeting, S1-5, Saratoga Springs, NY, 10-15 July 1999.
89. Mansour A., Hoversten M.T., Taylor L.P., Watson S.J., Akil H. The cloned mu, delta and kappa receptors and their endogenous ligands: evidence for two opioid peptide recognition cores. Brain Res. 700:1995;89-98.
90. Schiller P.W., Nguyen T.M., Weltrowska G., Wilkes B.C., Marsden B.J., Lemieux C., Chung N.N. Differential stereochemical requirements of mu vs. delta opioid receptors for ligand binding and signal transduction: development of a class of potent and highly delta-selective peptide antagonists. Proc. Natl. Acad. Sci. USA. 89:1992;11 871-11 875.
91. Pelton J.T., Gulya K., Hruby V.J., Duckles S.P., Yamamura H.I. Conformationally restricted analogs of somatostatin with high mu-opiate receptor specificity. Proc. Natl. Acad. Sci. USA. 82:1985;236-239.
92. Dooley C.T., Chung N.N., Schiller P.W., Houghten R.A. Acetalins: opioid receptor antagonists determined through the use of synthetic peptide combinatorial libraries. Proc. Natl. Acad. Sci. USA. 90:1993;10 811-10 815.
93. Morley J.S. The design of antagonists of regulatory peptides, and comments on their specificity. Prog. Brain Res. 66:1986;333-340.
94. 1]nociceptin analogs: receptor binding and bioassay studies, Naunyn. Schmiedebergs Arch. Pharmacol. (1999), in press.
95. + channel in Xenopus oocytes. Br. J. Pharmacol. 120:1997;986-987.
96. Noda Y., Mamiya T., Nabeshima T., Nishi M., Higashioka M., Takeshima H. Loss of antinociception induced by naloxone benzoylhydrazone in nociceptin receptor-knockout mice. J. Biol. Chem. 273:1998;18 047-18 051.
97. 1 receptors. Naunyn. Schmiedebergs Arch. Pharmacol. 358:1998;418-422.
98. Shah S., Page C.P., Spina D. Nociceptin inhibits non-adrenergic non-cholinergic contraction in guinea-pig airway. Br. J. Pharmacol. 125:1998;510-516.
99. Chu X., Xu N., Li P., Wang J.Q. The nociceptin receptor-mediated inhibition of the rat rostral ventrolateral medulla neurons in vitro. Eur. J. Pharmacol. 364:1999;49-53.
100. Gressens P., Calo' G., Evrard P. Nociceptin potentiates neonatal white matter excitotoxicity. Regul. Pept. 80:1999;123.
101. 1 receptor endogenously expressed in mouse N1E-115 neuroblastoma cells. Neuroreport. 10:1999;1127-1131.
102. 3H]5-HT release from the rat cerebral cortex in vitro, Br. J. Pharmacol. 126 (1999) 266P.
103. 2, a proposed antagonist of the nociceptin receptor, is a potent and stable agonist in the rat spinal cord. Neurosci. Lett. 249:1998;127-130.
104. 2 acts as an agonist of the orphanin FQ/nociceptin receptor in vivo. Eur. J. Pharmacol. 357:1998;R1-3.
105. 2 on nociception in rats (1998), in 29th International Narcotics Research Conference meeting A170, Garmisch-Partenkirchen, Germany, 20-25 July, 1998.
106. 1 receptor antagonist, acts as an agonist in the rat spinal cord. Br. J. Pharmacol. 125:1998;949-951.
107. 1) receptor. Eur. J. Pharmacol. 349:1998;R5-R6.
108. Wnendt S., Kruger T., Janocha E., Hildebrandt D., Englberger W. Agonistic effect of buprenorphine in a nociceptin/OFQ receptor-triggered reporter gene assay. Mol. Pharmacol. 56:1999;334-338.
109. Simon R.J., Kania R.S., Zuckermann R.N., Huebner V.D., Jewell D.A., Banville S., Ng S., Wang L., Rosenberg S., Marlowe C.K. et al. Peptoids: a modular approach to drug discovery. Proc. Natl. Acad. Sci. USA. 89:1992;9367-9371.
110. Horwell D.C. The 'peptoid' approach to the design of non-peptide, small molecule agonists and antagonists of neuropeptides. Trends Biotechnol. 13:1995;132-134.
111. Zuckermann R.N., Martin E.J., Spellmeyer D.C., Stauber G.B., Shoemaker K.R., Kerr J.M., Figliozzi G.M., Goff D.A., Siani M.A., Simon R.J. et al. Discovery of nanomolar ligands for 7-transmembrane G-protein-coupled receptors from a diverse N-(substituted)glycine peptoid library. J. Med. Chem. 37:1994;2678-2685.
112. 1 receptors to adenylyl cyclase. Br. J. Pharmacol. 123:1998;218P.
113. 1) receptor. Naunyn. Schmiedebergs Arch. Pharmacol. 359:1999;17-20.
114. Moore G.J. Designing peptide mimetics. Trends Pharmacol. Sci. 15:1994;124-129.
115. Rees D.C. Chemical structures and biological activities of non-peptide selective kappa opioid ligands. Prog. Med. Chem. 29:1992;109-139.
116. S. Ozaki, H. Kawamoto, Y. Ito, K. Hayashi, Y. Iwasawa, K. Hirano, Preparation of 2-oxaimidazole derivatives as pharmaceuticals, WO9854168-A1 (1998), Japan; C.A. 130:52418q (1999).
117. F. Jenck, F. Monsma, G. Galley, G. Adam, A. Cesura, S. Rover, J. Wichmann, Preparation of 8-benzocycloalkyl-1,3,8-triazaspiro-[4,5]decan-4-ones as orphanin FQ receptor ligands, EP856514-A1 (1998); C.A. 131:58825n (1999).